Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Wild-type and hereditary ATTR cardiomyopathy is increasingly recognized as a significant cause of heart failure with preserved ejection fraction in older…
In the NEURO-TTRansform Phase 3 trial of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, eplontersen 45 mg subcutaneously…
WAINUA (eplontersen) generated global net sales of $212 million in full-year 2025 (Q4 2025 $69M), yielding Ionis royalty revenue of $49 million for the year.…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
AstraZeneca and Ionis entered a global strategic collaboration to develop and commercialize eplontersen for transthyretin amyloidosis. AstraZeneca paid $200M upfront, up to $485M in conditional regulatory payments, plus up to $2.9B in sales-related milestones, totaling ~$3.585B. AZ leads ex-US (excluding Latin America); jointly developed/commercialized in US.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Ionis Pharmaceuticals, Inc. (this deal) | 2021 | $3.6B | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2021 deals · AstraZeneca PLC deals · Cardiovascular deals